Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug

MT Newswires Live10-16

Shenzhen Salubris Pharmaceuticals (SHE:002294) obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.

SAL0137 has the potential to treat elevated lipoprotein (a), a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.

Shares of the pharmaceutical company closed 3% higher Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575432967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575432967","market":"sh","top_or_hot":-1,"title":"Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/002294\">Shenzhen Salubris</a> Pharmaceuticals (SHE:002294) obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.</p><p>SAL0137 has the potential to treat elevated lipoprotein (a), a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.</p><p>Shares of the pharmaceutical company closed 3% higher Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-16 19:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/002294\">Shenzhen Salubris</a> Pharmaceuticals (SHE:002294) obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.</p><p>SAL0137 has the potential to treat elevated lipoprotein (a), a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.</p><p>Shares of the pharmaceutical company closed 3% higher Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575432967","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575432967","pubTimestamp":1760615588,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shenzhen Salubris Pharmaceuticals  obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.SAL0137 has the potential to treat elevated lipoprotein , a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 3% higher Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券","BK0196":"行业龙头","002294":"信立泰","BK0187":"一线龙头"},"translate_title":"深圳赛百利制药高脂蛋白药物临床试验申请获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":0.9},"content_text":"Shenzhen Salubris Pharmaceuticals (SHE:002294) obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.SAL0137 has the potential to treat elevated lipoprotein (a), a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 3% higher Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575432967","isCrawlerRequest":true}